Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AZP-3601
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alize Pharma 3 Announces Rebranding to Amolyt Pharma
Details : Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 02, 2020
Lead Product(s) : AZP-3601
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?